A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia - MGL9606

Madrigal Pharmaceuticals, Inc.0 sites24 target enrollmentTBD

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Not specified
Sponsor: Madrigal Pharmaceuticals, Inc.
Enrollment: 24
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Trial is onging in other countries

Registry

who.int

Start Date

TBD

End Date

January 15, 2018

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Madrigal Pharmaceuticals, Inc.

Eligibility Criteria

Inclusion Criteria

•Patients who meet all of the following criteria will be eligible to participate in the study:
•1\. Must be willing to participate in the study and provide written informed consent;
•2\. Male and female adults \*18 years of age;
•3\. Female patients of child bearing potential with negative serum pregnancy (beta human chorionic gonadotropin) test who are not breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control (ie, condoms, diaphragm, non\-hormonal intrauterine device \[IUD], or sexual abstinence \[only if this is in line with the patient\*s current lifestyle]) throughout the study and for at least 1 month after study completion; hormonal contraception (estrogens stable \*3 months) and hormonal IUDs are permitted if used with a secondary birth control measure (eg, condoms); OR female patients of non\-child bearing potential (ie, surgically \[bilateral oophorectomy, hysterectomy, or tubal ligation] or naturally sterile \[\>12 consecutive months without menses]); male patients who have sexual intercourse with a female partner of child bearing potential from the first dose of study drug until 1 month after study completion must either be surgically sterile (confirmed by documented azoospermia \>90 days after the procedure) OR agree to use a condom with spermicide. All male patients must agree not to donate sperm from the first dose of study drug until 1 month after study completion;
•4\. Must have a diagnosis of HeFH by genetic testing or by having met the diagnostic criteria for definite familial hypercholesterolemia outlined by the Simon Broome Register Group (Appendix C) or WHO/Dutch Lipid Network (score \>8; Appendix D);
•5\. Must have a fasting LDL\-C \*2\.6 mmol/L (100 mg/dL).
•Any one of the following subgroups of patients with documented history of cardiovascular disease as outlined below can be included with a fasting LDL\-C of \* 1\.8 mmol/L (70 mg/dL):
•A) Coronary Artery Disease (CAD) including one or more of the following:
•\* Acute myocardial infarction (MI)
•\* Silent myocardial infarction

Exclusion Criteria

•Patients who meet any of the following criteria will be excluded from participation in the study:
•1\. Homozygous familial hypercholesterolemia;
•2\. Low\-density lipoprotein (LDL) or plasma apheresis within 2 months prior to randomization;
•3\. New York Heart Association class III or IV heart failure, or known left ventricular ejection fraction \<30%;
•4\. Uncontrolled cardiac arrhythmia, including confirmed QT interval corrected using Fridericia\*s formula (QTcF) \>450 msec for males and \>470 msec for females at the screening electrocardiogram (ECG) assessment;
•5\. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within 3 months prior to randomization;
•6\. Type 1 diabetes, or newly diagnosed or uncontrolled type 2 diabetes (hemoglobin A1c \[HbA1c] \>8%);
•7\. History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening; Note: Significant alcohol consumption is defined as average of \>20 g/day in female patients and \>30 g/day in male patients;
•8\. Hyperthyroidism;
•9\. Thyroid replacement therapy;